Biology Reference
In-Depth Information
104. Murata S, Herman P, Lakowicz JR. Texture analysis of fluorescence lifetime images of
AT- and GC-rich regions in nuclei.
J Histochem Cytochem
2001;49:1443-51.
105. Murata S, Herman P, Lakowicz JR. Texture analysis of fluorescence lifetime images of
nuclear DNA with effect of
fluorescence resonance energy transfer.
Cytometry
2001;43:94-100.
106. Rizzo MA, Springer GH, Granada B, Piston DW. An improved cyan fluorescent pro-
tein variant useful for FRET.
Nat Biotechnol
2004;22:445-9.
107. Goedhart J, van Weeren L, Hink MA, Vischer NOE, Jalink K, Gadella TWJ. Bright
cyan fluorescent protein variants identified by fluorescence lifetime screening.
Nat
Methods
2010;7:137-9.
108. Kurzrock R, Estrov Z, Kantarjian H, Talpaz M. Conversion of interferon-induced,
long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase
chain reaction negativity.
J Clin Oncol
1998;16:1526-31.
109. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Phil-
adelphia chromosomal breakpoints are clustered within a limited region, bcr, on chro-
mosome 22.
Cell
1984;36:93-9.
110. Heisterkamp N, Groffen J, Stephenson JR, Spurr NK, Goodfellow PN, Solomon E,
et al. Chromosomal localization of human cellular homologues of two viral oncogenes.
Nature
1982;
:747-9.
111. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML.
Blood
2008;112:4808-17.
112. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a
selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.
Nat Med
1996;2:561-6.
113. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second gener-
ation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid
leukaemia.
Nat Rev Cancer
2007;7:345-56.
114. Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA, et al. Survival
advantage from imatinib compared with the combination interferon-alpha plus
cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison
between two phase 3 trials.
Blood
2006;108:1478-84.
115. Feller SM. Crk family adaptors-signalling complex formation and biological roles.
Oncogene
2001;20:6348-71.
116. Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW. Identification of
CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic
myelogenous leukemia cells.
Blood
1994;84:2912-8.
117. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ. Crkl is the major
tyrosine-phosphorylated protein in neutrophils from patients with chronic myeloge-
nous leukemia.
J Biol Chem
1994;269:22925-8.
118. ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J. Tyrosine phosphor-
ylation of CRKL in Philadelphia
รพ
leukemia.
Blood
1994;84:1731-6.
119. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, et al. In vitro ac-
tivity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant
imatinib-resistant Abl kinase domain mutants.
Cancer Res
2005;
299
:4500-5.
120. Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M, et al. Activity
of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
J Clin Oncol
2009;27:469-71.
121. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical
resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplifi-
cation.
Science
2001;293:876-80.
122. Lu S, Wang Y. Fluorescence resonance energy transfer biosensors for cancer detection
and evaluation of drug efficacy.
Clin Cancer Res
2010;16:3822-4.
65
Search WWH ::
Custom Search